Cargando…

Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment

Introduction: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract. Biologic drugs target specific molecules in the body’s immune system to control inflammation. Recent studies have suggested a potential link between their use and an increased risk of nephrolit...

Descripción completa

Detalles Bibliográficos
Autores principales: Alameddine, Zakaria, Abi Melhem, Racha, Dimachkie, Reem, Rabah, Hussein, Chehab, Hamed, El Khoury, Michel, Qaqish, Faris, Stefanov, Dimitre, El-Sayegh, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573832/
https://www.ncbi.nlm.nih.gov/pubmed/37834757
http://dx.doi.org/10.3390/jcm12196114
_version_ 1785120552496660480
author Alameddine, Zakaria
Abi Melhem, Racha
Dimachkie, Reem
Rabah, Hussein
Chehab, Hamed
El Khoury, Michel
Qaqish, Faris
Stefanov, Dimitre
El-Sayegh, Suzanne
author_facet Alameddine, Zakaria
Abi Melhem, Racha
Dimachkie, Reem
Rabah, Hussein
Chehab, Hamed
El Khoury, Michel
Qaqish, Faris
Stefanov, Dimitre
El-Sayegh, Suzanne
author_sort Alameddine, Zakaria
collection PubMed
description Introduction: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract. Biologic drugs target specific molecules in the body’s immune system to control inflammation. Recent studies have suggested a potential link between their use and an increased risk of nephrolithiasis. We conducted a study to further investigate this association. Methods: The study used multiple logistic regression analysis to assess the association between the use of biologic drugs and nephrolithiasis. A p-value of <0.05 was considered statistically significant. SAS 9.4 was used for statistical analysis. Results: The final sample consisted of 22,895 cases, among which 5603 (24.51%) were receiving at least one biologic drug. The biologic drugs received were as follows: Adalimumab 2437 (10.66%), Infliximab 1996 (8.73%), Vedolizumab 1397 (6.11%), Ustekinumab 1304 (5.70%); Tofacitinib, 308 (1.35%); Certolizumab, 248 (1.08%); and Golimumab, 121 (0.53%). There were 1780 (7.74%) patients with Nephrolithiasis: 438 (8.0%) patients were receiving biologic treatment. We found that the use of Vedolizumab (OR = 1.307, 95% CI 1.076–1.588, p = 0.0071) increased the odds of Nephrolithiasis by 31%. Conclusion: Vedolizumab use was associated with an increased risk of nephrolithiasis. The use of two or more biologic drugs also increased the risk compared to no biologic treatment.
format Online
Article
Text
id pubmed-10573832
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105738322023-10-14 Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment Alameddine, Zakaria Abi Melhem, Racha Dimachkie, Reem Rabah, Hussein Chehab, Hamed El Khoury, Michel Qaqish, Faris Stefanov, Dimitre El-Sayegh, Suzanne J Clin Med Brief Report Introduction: Inflammatory bowel disease is a chronic inflammatory disorder of the gastrointestinal tract. Biologic drugs target specific molecules in the body’s immune system to control inflammation. Recent studies have suggested a potential link between their use and an increased risk of nephrolithiasis. We conducted a study to further investigate this association. Methods: The study used multiple logistic regression analysis to assess the association between the use of biologic drugs and nephrolithiasis. A p-value of <0.05 was considered statistically significant. SAS 9.4 was used for statistical analysis. Results: The final sample consisted of 22,895 cases, among which 5603 (24.51%) were receiving at least one biologic drug. The biologic drugs received were as follows: Adalimumab 2437 (10.66%), Infliximab 1996 (8.73%), Vedolizumab 1397 (6.11%), Ustekinumab 1304 (5.70%); Tofacitinib, 308 (1.35%); Certolizumab, 248 (1.08%); and Golimumab, 121 (0.53%). There were 1780 (7.74%) patients with Nephrolithiasis: 438 (8.0%) patients were receiving biologic treatment. We found that the use of Vedolizumab (OR = 1.307, 95% CI 1.076–1.588, p = 0.0071) increased the odds of Nephrolithiasis by 31%. Conclusion: Vedolizumab use was associated with an increased risk of nephrolithiasis. The use of two or more biologic drugs also increased the risk compared to no biologic treatment. MDPI 2023-09-22 /pmc/articles/PMC10573832/ /pubmed/37834757 http://dx.doi.org/10.3390/jcm12196114 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Alameddine, Zakaria
Abi Melhem, Racha
Dimachkie, Reem
Rabah, Hussein
Chehab, Hamed
El Khoury, Michel
Qaqish, Faris
Stefanov, Dimitre
El-Sayegh, Suzanne
Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment
title Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment
title_full Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment
title_fullStr Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment
title_full_unstemmed Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment
title_short Risk of Nephrolithiasis in Patients with Inflammatory Bowel Disease Receiving Biologic Treatment
title_sort risk of nephrolithiasis in patients with inflammatory bowel disease receiving biologic treatment
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573832/
https://www.ncbi.nlm.nih.gov/pubmed/37834757
http://dx.doi.org/10.3390/jcm12196114
work_keys_str_mv AT alameddinezakaria riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment
AT abimelhemracha riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment
AT dimachkiereem riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment
AT rabahhussein riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment
AT chehabhamed riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment
AT elkhourymichel riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment
AT qaqishfaris riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment
AT stefanovdimitre riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment
AT elsayeghsuzanne riskofnephrolithiasisinpatientswithinflammatoryboweldiseasereceivingbiologictreatment